Quinolin(on)es and pyridin(on)es as promising scaffolds against mycobacterial infections
Abstract
Mycobacterial infections pose a significant global health challenge. In 2024, 1.23 million deaths were associated with M. tuberculosis (M.tb). In recent years, the number of recorded cases of non-tuberculous mycobacterial infections has risen, particularly among elderly patients or people with underlying pulmonary diseases. Due to the emergence of antibioresistance, the discovery of new drugs which target essential enzymes in mycobacteria is required to move towards new therapeutic options for future years. Some current clinical drugs contain promising scaffolds, which serve as a basis for other researches in medicinal chemistry. The increasing interest of quinoline, quinolone, pyridine and pyridone cores is driven by their promising biological effects, initially as antibacterial agents, and more specifically, as antimycobacterial agents. The drug discovery strategy focuses on three main biological targets: the mycolic acids biosynthesis, the mycobacterial energy metabolism and DNA metabolism. Hence, this review aims to highlight the development of novel antimycobacterial agents, based on these four promising scaffolds by presenting the design strategy and biological results of recent studies.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.